Reproductive Endocrinology Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Reproductive Endocrinology Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Fertil Steril. 2018 Dec;110(7):1377-1386. doi: 10.1016/j.fertnstert.2018.08.046.
To evaluate the incidence of hypertension, metabolic syndrome, dyslipidemia, and obesity in comparing women with polycystic ovary syndrome (PCOS) and a control group of healthy women.
Prospective cohort study with the median and interquartile range of 12.9 (10.8-13.9) years.
Population-based cohort of the Tehran Lipid and Glucose Study.
PATIENT(S): A total of 1,702 reproductive-age women including 178 women with PCOS and 1,524 controls.
INTERVENTION(S): None.
MAIN OUTCOME MEASURE(S): Cumulative incidence of each outcome estimated using the Kaplan-Meier method and compared using the log-rank statistic; univariate and multiple extended Cox proportional hazards regression with age as the time scale to estimate the adjusted hazard ratio (HR) of developing outcomes in relation to PCOS and ages ≤40 years and >40 years with heavyside functions.
RESULT(S): The incidence rates of hypertension, metabolic syndrome, dyslipidemia, and obesity were 13.9, 21.0, 46.1, 24.6, and 50.6, respectively, per 1,000 person-years for women with PCOS; and 13.8, 22.7, 46.0, and 24.0, respectively, per 1,000 person-years for the healthy control women. Women with PCOS aged ≤40 years had an adjusted higher risk of developing hypertension (HR 2.08; 95% confidence interval, 1.0-3.9) and the metabolic syndrome (HR 1.81; 95% confidence interval, 1.1-2.9), but the risk disappeared after age 40. The risks of central obesity and obesity had borderline statistical significance and were higher in women with PCOS aged ≤40 than in healthy controls. The risk of developing dyslipidemia showed no statistically significant difference between the two groups in the unadjusted or multiple adjusted models at any age.
CONCLUSION(S): In this long-term population-based cohort study, the risk of developing hypertension and the metabolic syndrome in young women with PCOS was higher than in controls, but these risks were diluted in the late reproductive period.
评估比较多囊卵巢综合征（PCOS）患者与健康对照组女性的高血压、代谢综合征、血脂异常和肥胖的发生率。
前瞻性队列研究，中位数和四分位距为 12.9（10.8-13.9）年。
德黑兰血脂和血糖研究的基于人群的队列。
共纳入 1702 名育龄期妇女，包括 178 名 PCOS 患者和 1524 名对照组。
无。
采用 Kaplan-Meier 法估计每种结局的累积发生率，并采用对数秩检验进行比较；采用单变量和多变量扩展 Cox 比例风险回归，以年龄为时间尺度，估计与 PCOS 相关的结局的调整后风险比（HR）以及年龄≤40 岁和>40 岁的 HR，采用 heavyside 函数。
PCOS 组女性高血压、代谢综合征、血脂异常和肥胖的发生率分别为每 1000 人年 13.9、21.0、46.1、24.6 和 50.6 例；健康对照组女性的发生率分别为每 1000 人年 13.8、22.7、46.0 和 24.0 例。年龄≤40 岁的 PCOS 组女性发生高血压的调整后风险更高（HR 2.08；95%置信区间，1.0-3.9）和代谢综合征（HR 1.81；95%置信区间，1.1-2.9），但 40 岁后风险消失。中心性肥胖和肥胖的风险具有边缘统计学意义，且年龄≤40 岁的 PCOS 女性高于健康对照组。在未调整或多因素调整模型中，两组在任何年龄发生血脂异常的风险均无统计学差异。
在这项长期的基于人群的队列研究中，年轻 PCOS 女性发生高血压和代谢综合征的风险高于对照组，但在生殖后期风险降低。
